SCHEMBL95686

SCHEMBL95686

CCOC(=O)C(=NO)c1csc(N)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.62
KMT2A Q03164 9/20 0.62
MAPT P10636 8/20 0.62
ALDH1A1 P00352 4/20 0.62
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
LMNA P02545 2/20 0.54
MAPK1 P28482 2/20 0.54
GAA P10253 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
RECQL P46063 1/20 0.46
TSHR P16473 2/20 0.43
HTT P42858 3/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 2/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9659527 1.00 MEN1 (0.62) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL95685 1.00 MEN1 (0.62) MEN1KMT2AMAPTALDH1A1NPC1
Hydrochloric Acid SCHEMBL9076121 0.99 MEN1 (0.65) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL10538827 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL1143128 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL8645013 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL8645016 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL1143127 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL9076641 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL4837027 0.85 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6180238-B1 PARTICULARLY SUITABLE FOR USE IN INK JET PRINTING PROCESSES. XEROX CORPORATION 2001-01-30 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0673784-B1 Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds XEROX CORP (US) 1999-10-27 EP claimed
EP-0555769-B1 Process for the preparation of Cephem-Prodrug-esters HOECHST AG (DE) 1999-09-15 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0673784-A2 Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds XEROX CORPORATION (US) 1995-09-27 EP claimed
US-4988816-A Chemical intermediates for cephalosporin antibiotics ROUSSEL UCLAF (FR) 1991-01-29 US claimed
JP-7173140-A None JP disclosed
JP-7082253-A None JP disclosed
JP-7179445-A None JP disclosed
US-20230114728-A1 PENICILLIN-BINDING PROTEIN INHIBITORS VenatoRx Pharmaceuticals, Inc. 2023-04-13 US disclosed
US-11332485-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2022-05-17 US disclosed
US-4203899-A Thiazolylacetamido compounds TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-05-20 US disclosed
US-4196205-A ANTIBIOTICS, BACTERICIDES ROUSSEL UCLAF (FR) 1980-04-01 US disclosed
US-4166115-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-08-28 US disclosed
US-4152432-A ANTIBIOTICS ROUSSEL UCLAF (FR) 1979-05-01 US disclosed
US-4098888-A THIAZOLYLACETAMIDO CEPHALOSPORIN TYPE COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1978-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114728-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL MEN1 3629/4885KMT2A 2536/4885MAPT 3146/4885
US-11332485-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL MEN1 3629/4885KMT2A 2536/4885MAPT 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.